Newland Pharmaceutical Co., Ltd. (SHE:301277)

Newland Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	684.42	719.43	643.85	621.21	508.93	429.75
Other Revenue	4.06	7	7.59	6.15	4.91	3.38
Revenue	688.48	726.44	651.44	627.36	513.84	433.12
Revenue Growth (YoY)	-3.58%	11.51%	3.84%	22.09%	18.63%	6.54%
Cost of Revenue	431.99	437.43	392.84	404.01	307.82	236.31
Gross Profit	256.49	289	258.6	223.36	206.02	196.81
Selling, General & Admin	52.88	47.62	44.49	38.83	31.56	25.3
Research & Development	57.61	55.49	51.96	30	20.59	20.62
Other Operating Expenses	2.42	2.71	3.89	6.99	6.4	5.83
Operating Expenses	110.72	108.1	96.75	78.04	69.69	53.99
Operating Income	145.77	180.91	161.85	145.31	136.33	142.82
Interest Expense	-0.03	-0.09	-0.13	-6.88	-6.71	-3.8
Interest & Investment Income	13.63	16.7	19.63	1.34	0.26	0.08
Currency Exchange Gain (Loss)	0.12	0.25	0.06	0.29	-0.13	-0.35
Other Non Operating Income (Expenses)	-0.33	-0.06	-0.12	-0.09	-0.06	-0.02
EBT Excluding Unusual Items	159.17	197.7	181.29	139.97	129.69	138.74
Gain (Loss) on Sale of Investments	-0.44	-0.23	0.04	1.36	0.17	-
Gain (Loss) on Sale of Assets	0.49	-	0.07	-0.44	-0.21	-0.12
Asset Writedown	-5.72	-2.62	-1.46	-0.32	-0.11	-
Legal Settlements	-	-	-	-	-	-3
Other Unusual Items	2.48	2.5	1.22	2.31	2.4	1.81
Pretax Income	155.99	197.35	181.16	142.88	131.94	137.43
Income Tax Expense	15.54	24.34	23.96	11.17	17.11	18.97
Earnings From Continuing Operations	140.45	173.01	157.2	131.71	114.82	118.46
Minority Interest in Earnings	-0.29	0.62	1.78	0.6	0.15	-
Net Income	140.16	173.63	158.98	132.3	114.98	118.46
Net Income to Common	140.16	173.63	158.98	132.3	114.98	118.46
Net Income Growth	-20.71%	9.21%	20.16%	15.07%	-2.94%	8.52%
Shares Outstanding (Basic)	392	392	391	302	294	292
Shares Outstanding (Diluted)	392	392	391	302	294	292
Shares Change (YoY)	1.32%	0.39%	29.52%	2.59%	0.64%	0.34%
EPS (Basic)	0.36	0.44	0.41	0.44	0.39	0.41
EPS (Diluted)	0.36	0.44	0.41	0.44	0.39	0.40
EPS Growth	-21.74%	8.79%	-7.22%	12.17%	-3.36%	8.18%
Free Cash Flow	-34.85	15.97	162.94	8.5	23.68	30.9
Free Cash Flow Per Share	-0.09	0.04	0.42	0.03	0.08	0.11
Dividend Per Share	0.286	0.286	0.204	0.170	-	-
Dividend Growth	39.98%	39.98%	19.99%	-	-	-
Gross Margin	37.26%	39.78%	39.70%	35.60%	40.09%	45.44%
Operating Margin	21.17%	24.90%	24.85%	23.16%	26.53%	32.98%
Profit Margin	20.36%	23.90%	24.40%	21.09%	22.38%	27.35%
Free Cash Flow Margin	-5.06%	2.20%	25.01%	1.35%	4.61%	7.13%
EBITDA	189.42	215.99	190.69	167.38	157.19	160.77
EBITDA Margin	27.51%	29.73%	29.27%	26.68%	30.59%	37.12%
D&A For EBITDA	43.65	35.09	28.84	22.06	20.86	17.95
EBIT	145.77	180.91	161.85	145.31	136.33	142.82
EBIT Margin	21.17%	24.90%	24.85%	23.16%	26.53%	32.98%
Effective Tax Rate	9.96%	12.33%	13.23%	7.82%	12.97%	13.80%
Revenue as Reported	688.48	726.44	651.44	627.36	513.84	-
Advertising Expenses	-	0.85	0.51	0.2	0.28	0.19

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.